期刊文献+

Enzalutamide (formerly MDV3100) as a new !herapeutic option for men with metastatic castration-resistant prostate cancer 被引量:2

Enzalutamide (formerly MDV3100) as a new !herapeutic option for men with metastatic castration-resistant prostate cancer
下载PDF
导出
摘要 Enzalutamide marks the latest addition to the drugs currently approved by the US Food and Drug Administration for metastatic, castration-resistant prostate can- cer (mCRPC). Enzalutamide marks the latest addition to the drugs currently approved by the US Food and Drug Administration for metastatic, castration-resistant prostate can- cer (mCRPC).
机构地区 Department of Medicine
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2012年第6期805-806,共2页 亚洲男性学杂志(英文版)
  • 相关文献

同被引文献5

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部